Active

The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial

Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months

Prospective
Study Type
30/40
Participants
Jan 2024
Started

Project Overview

Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months

Research Objectives

A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.

Study Details

Study Type

Prospective

Status

Active

Start Date

January 01, 2024

Participant Progress

Enrolled 30 / 40

Quick Actions

View Details Back to Research

Study Information

Study Type: Prospective
Status: Active
Started: Jan 2024
Participants: 30/40

Get Involved

Interested in participating in this research study or have questions? Contact our research team for more information.

Contact Research Team

Related Research Projects

Explore other ongoing research initiatives that may be of interest.

View All Research Projects